Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms
暂无分享,去创建一个
R. Salazar | J. Tabernero | R. Rosell | M. Taron | J. Ramírez | J. Maurel | A. Font | E. Carcereny | R. Gallego | J. Manzano | E. Casado | M. Guix | J. Fernández-Llamazares
[1] V. Catalano,et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy , 2008, The Pharmacogenomics Journal.
[2] J. Ajani,et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Giuseppe Toffoli,et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] G. Watanabe,et al. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Taron,et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] C. Guillemette,et al. Irinotecan Inactivation Is Modulated by Epigenetic Silencing of UGT1A1 in Colon Cancer , 2006, Clinical Cancer Research.
[7] J. Ajani,et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[9] M. Raderer,et al. Palliative chemotherapy for advanced gastric cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] M. Taron,et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] M. Baiget,et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer , 2004, British Journal of Cancer.
[12] D. Neuberg,et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Soma Das,et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] R. Rosell,et al. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism , 2003, Investigational New Drugs.
[15] C. Guillemette,et al. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). , 2002, Molecular pharmacology.
[16] R. Rosell,et al. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors. , 2002, Lung cancer.
[17] T. Hickish,et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] S. Groshen,et al. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. , 2001, Cancer research.
[19] P Vineis,et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. , 2001, Carcinogenesis.
[20] C I Amos,et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. , 2001, Cancer research.
[21] H. Lippert,et al. Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] H. Saka,et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. , 2000, Cancer research.
[23] E. Van Cutsem,et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] F. Cavalli,et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] G. Schwartz,et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] A. Di Rienzo,et al. Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism , 1999, Clinical pharmacology and therapeutics.
[27] W. de Laat,et al. Molecular mechanism of nucleotide excision repair. , 1999, Genes & development.
[28] I. Hyodo,et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] I. Judson,et al. First demonstration of anti-lymphoma activity of BCL-2 antisense molecule-G3139; Results of phase I/IIA clinical trial , 1997 .
[30] M. Oka,et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] T. Hickish,et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. , 1997, Journal of Clinical Oncology.
[32] C. McArdle,et al. Chemotherapy in advanced gastric cancer. , 1985, Cancer treatment reports.